Efficacy and safety of single-dose zoledronic acid for osteoporosis in frail elderly women a randomized clinical trial

JAMA Internal Medicine

Volumn 175, Issue 6, 2015, Pages 913-921

  Greenspan, Susan L ^a   Perera, Subashan ^a,b   Ferchak, Mary Anne ^a   Nace, David A ^a   Resnick, Neil M ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; BIOCHEMICAL MARKER; CALCIUM; PLACEBO; VITAMIN D; ZOLEDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; BONE DENSITY CONSERVATION AGENT; IMIDAZOLE DERIVATIVE;

AGED; ARTHRALGIA; ARTICLE; ASSISTED LIVING FACILITY; ATRIAL FIBRILLATION; BONE DENSITY; BONE TURNOVER; COGNITIVE DEFECT; CONTROLLED STUDY; DIABETES MELLITUS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FALLING; FATIGUE; FEMALE; FEVER; FLU LIKE SYNDROME; FRAGILITY FRACTURE; FRAIL ELDERLY; HEADACHE; HIP; HUMAN; IMMOBILITY; LONG TERM CARE; MAJOR CLINICAL STUDY; MEDICAL HISTORY; MENTAL HEALTH; MORTALITY; NURSING HOME; OSTEOPOROSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; SPINE; SPINE FRACTURE; VITAMIN SUPPLEMENTATION; BONE REMODELING; DRUG EFFECTS; INTRAVENOUS DRUG ADMINISTRATION; VERY ELDERLY;

AGED, 80 AND OVER; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; BONE REMODELING; DIPHOSPHONATES; DOUBLE-BLIND METHOD; FEMALE; HUMANS; IMIDAZOLES; INFUSIONS, INTRAVENOUS; OSTEOPOROSIS;

EID: 84930699008     PISSN: 21686106     EISSN: 21686114     Source Type: Journal    
DOI: 10.1001/jamainternmed.2015.0747     Document Type: Article

References (52)

1. Kelsey JL, Hoffman S. Risk factors for hip fracture. N Engl J Med.1987;316(7):404-406.
2. Zimmerman SI, Girman CJ, Buie VC, et al. The prevalence of osteoporosis in nursing home residents.Osteoporos Int. 1999;9(2):151-157.
3. Chandler JM, Zimmerman SI, Girman CJ, et al. Low bone mineral density and risk of fracture in white female nursing home residents. JAMA. 2000;284(8):972-977.
4. Greenspan SL, Perera S, Nace D, et al. FRAX or fiction: determining optimal screening strategies for treatment of osteoporosis in residents in long-term care facilities. J Am Geriatr Soc. 2012;60(4):684-690.
5. US Department of Health and Human Services. Bone Health and Osteoporosis: A Report of the Surgeon General. Rockville, MD: US Department of Health and Human Services, Office of the Surgeon General; 2004.
6. Lyles KW, Schenck AP, Colón-Emeric CS. Hip and other osteoporotic fractures increase the risk of subsequent fractures in nursing home residents. Osteoporos Int. 2008;19(8):1225-1233.
7. Zimmerman S, Chandler JM, Hawkes W, et al. Effect of fracture on the health care use of nursing home residents. Arch Intern Med. 2002;162(13):1502-1508.
8. Neuman MD, Silber JH, Magaziner JS, Passarella MA, Mehta S, Werner RM. Survival and functional outcomes after hip fracture among nursing home residents. JAMA Intern Med. 2014;174(8):1273-1280.
9. Beaupre LA, Majumdar SR, Dieleman S, Au A, Morrish DW. Diagnosis and treatment of osteoporosis before and after admission to long-term care institutions. Osteoporos Int. 2012;23(2):573-580.
10. Parikh S, Mogun H, Avorn J, Solomon DH. Osteoporosis medication use in nursing home patients with fractures in 1 US state. Arch Intern Med. 2008;168(10):1111-1115.
11. Boonen S, Black DM, Colón-Emeric CS, et al. Efficacy and safety of a once-yearly intravenous zoledronic acid 5 mg for fracture prevention in elderly postmenopausal women with osteoporosis aged 75 and older. J Am Geriatr Soc. 2010;58(2):292-299.
12. Boonen S, Marin F, Mellstrom D, et al. Safety and efficacy of teriparatide in elderly women with established osteoporosis: bone anabolic therapy from a geriatric perspective. J Am Geriatr Soc. 2006;54(5):782-789.
13. Torring O, Lippuner K, Adachi J, et al. The effect of denosumab on risk of fracture over 3 years among elderly postmenopausal women: results from the Freedom Trial: 11th-EULAR-2010 2010 [abstract SAT0357]. http://www.eular.org. Accessed February 24, 2015.
14. Parfitt AM. Trabecular bone architecture in the pathogenesis and prevention of fracture. Am J Med. 1987;82(1B):68-72.
15. Seeman E. Is a change in bone mineral density a sensitive and specific surrogate of anti-fracture efficacy? Bone. 2007;41(3):308-317.
16. Bouxsein ML. Determinants of skeletal fragility. Best Pract Res Clin Rheumatol. 2005;19(6):897-911.
17. McClung MR, Geusens P, Miller PD, et al Hip Intervention Program Study Group. Effect of risedronate on the risk of hip fracture in elderly women. N Engl J Med. 2001;344(5):333-340.
18. Khosla S, Bellido TM, Drezner MK, et al. Forum on aging and skeletal health: summary of the proceedings of an ASBMR workshop. J Bone Miner Res. 2011;26(11):2565-2578.
19. Compston JE, Papapoulos SE, Blanchard F; Working Party from European Union Member States. Report on osteoporosis in the European Community: current status and recommendations for the future. Osteoporos Int. 1998;8(6):531-534.
20. NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy. Osteoporosis prevention, diagnosis, and therapy. JAMA. 2001;285(6):785-795.
21. US Department of Health and Human Services. Systems-Based Approaches to Bone Health. Bone Health and Osteoporosis: A report of the Surgeon General. Rockville, MD: US Department of Health and Human Services, Office of the Surgeon General; 2004:281-304.
22. Greenspan S, Nace D, Perera S, et al. Lessons learned from an osteoporosis clinical trial in frail long-term care residents. Clin Trials. 2012;9(2):247-256.
23. Hochberg MC, Ross PD, Black D, et al Fracture Intervention Trial Research Group. Larger increases in bone mineral density during alendronate therapy are associated with a lower risk of new vertebral fractures in women with postmenopausal osteoporosis. Arthritis Rheum. 1999;42(6):1246-1254.
24. Hochberg MC, Greenspan S, Wasnich RD, Miller P, Thompson DE, Ross PD. Changes in bone density and turnover explain the reductions in incidence of nonvertebral fractures that occur during treatment with antiresorptive agents. J Clin Endocrinol Metab. 2002;87(4):1586-1592.
25. Bolland MJ, Grey AB, Horne AM, et al. Effects of intravenous zoledronate on bone turnover and BMD persist for at least 24 months. J Bone Miner Res. 2008;23(8):1304-1308.
26. Grey A, Bolland MJ, Wattie D, Horne A, Gamble G, Reid IR. The antiresorptive effects of a single dose of zoledronate persist for two years: a randomized, placebo-controlled trial in osteopenic postmenopausal women. J Clin Endocrinol Metab. 2009;94(2):538-544.
27. National Osteoporosis Foundation. Physician's Guide to Prevention and Treatment of Osteoporosis. Belle Mead, NJ: Excerpta Medica; 2003.
28. Kanis JA; WHO Study Group. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: synopsis of a WHO report. Osteoporos Int. 1994;4(6):368-381.
29. Lips P. Vitamin D deficiency and secondary hyperparathyroidism in the elderly: consequences for bone loss and fractures and therapeutic implications. Endocr Rev. 2001;22(4):477-501.
30. Dawson-Hughes B, Jacques P, Shipp C. Dietary calcium intake and bone loss from the spine in healthy postmenopausal women. Am J Clin Nutr. 1987;46(4):685-687.
31. Kanis JA. Diagnosis of osteoporosis and assessment of fracture risk. Lancet. 2002;359(9321):1929-1936.
32. Black DM, Delmas PD, Eastell R, et al HORIZON Pivotal Fracture Trial. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med. 2007;356(18):1809-1822.
33. Varney LF, Parker RA, Vincelette A, Greenspan SL. Classification of osteoporosis and osteopenia in postmenopausal women is dependent on site-specific analysis.J Clin Densitom. 1999;2(3):275-283.
34. Genant HK, Jergas M, Palermo L, et al. Comparison of semiquantitative visual and quantitative morphometric assessment of prevalent and incident vertebral fractures in osteoporosis: The Study of Osteoporotic Fractures Research Group. J Bone Miner Res. 1996;11(7):984-996.
35. Sullivan S, Wagner J, Resnick NM, Nelson J, Perera SK, Greenspan SL. Vertebral fractures and the misclassification of osteoporosis in men with prostate cancer. J Clin Densitom. 2011;14(3):348-353.
36. Katz S, Ford AB, Moskowitz RW, Jackson BA, Jaffe MW. Studies of illness in the aged: the index of ADL: a standardized measure of biological and psychosocial function. JAMA. 1963;185:914-919.
37. Lawton MP, Brody EM. Assessment of older people: self-maintaining and instrumental activities of daily living. Gerontologist. 1969;9(3):179-186.
38. Studenski S, Perera S, Patel K, et al. Gait speed and survival in older adults. JAMA. 2011;305(1):50-58.
39. Abellan van Kan G, Rolland Y, Houles M, Gillette-Guyonnet S, Soto M, Vellas B. The assessment of frailty in older adults. Clin Geriatr Med. 2010;26(2):275-286.
40. Pfeiffer E. A short portable mental status questionnaire for the assessment of organic brain deficit in elderly patients. J Am Geriatr Soc.1975;23(10):433-441.
41. Rigler SK, Studenski S, Wallace D, Reker DM, Duncan PW. Co-morbidity adjustment for functional outcomes in community-dwelling older adults. Clin Rehabil. 2002;16(4):420-428.
42. Kroenke K, Spitzer RL. The PHQ-9: a new depression and diagnostic severity measure. Psychiatr Ann. 2002;32(9):509-521.
43. Fried LP, Tangen CM, Walston J, et al Cardiovascular Health Study Collaborative Research Group. Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci. 2001;56(3):M146-M156.
44. Binder EF, Miller JP, Ball LJ. Development of a test of physical performance for the nursing home setting. Gerontologist. 2001;41(5):671-679.
45. Reid IR, Brown JP, Burckhardt P, et al. Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl J Med. 2002;346(9):653-661.
46. Trevisan C, Bigoni M, Cherubini R, Steiger P, Randelli G, Ortolani S. Dual X-ray absorptiometry for the evaluation of bone density from the proximal femur after total hip arthroplasty: analysis protocols and reproducibility. Calcif Tissue Int. 1993;53(3):158-161.
47. Rubin DB. Multiple Imputation for Nonresponse in Surveys. New York, NY: John Wiley & Sons Ltd; 1987.
48. Rubin DB. Multiple imputation after 18+ years. Stat Med. 1991;14:1913-1925.
49. Greenspan SL, Schneider DL, McClung MR, et al. Alendronate improves bone mineral density in elderly women with osteoporosis residing in long-term care facilities: a randomized, double-blind, placebo-controlled trial. Ann Intern Med. 2002;136(10):742-746.
50. Kraemer HC, Mintz J, Noda A, Tinklenberg J, Yesavage JA. Caution regarding the use of pilot studies to guide power calculations for study proposals. Arch Gen Psychiatry. 2006;63(5):484-489.
51. Tinetti ME, Williams CS. Falls, injuries due to falls, and the risk of admission to a nursing home. N Engl J Med. 1997;337(18):1279-1284.
52. Karlsson MK, Magnusson H, von Schewelov T, Rosengren BE. Prevention of falls in the elderly: a review. Osteoporos Int. 2013;24(3):747-762.